In the last trading session, 1.43 million Nektar Therapeutics (NASDAQ:NKTR) shares changed hands as the company’s beta touched 0.54. With the company’s per share price at $0.69 changed hands at $0.01 or 0.74% during last session, the market valuation stood at $127.48M. NKTR’s last price was a discount, traded about -165.22% off its 52-week high of $1.83. The share price had its 52-week low at $0.43, which suggests the last value was 37.68% up since then.
Analysts gave the Nektar Therapeutics (NKTR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.75. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended NKTR as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Nektar Therapeutics’s EPS for the current quarter is expected to be -0.19.
Nektar Therapeutics (NASDAQ:NKTR) trade information
Instantly NKTR was in green as seen at the end of in last trading. With action 16.36%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -26.34%, with the 5-day performance at 16.36% in the green. However, in the 30-day time frame, Nektar Therapeutics (NASDAQ:NKTR) is 12.89% up.
The consensus price target for the stock as assigned by Wall Street analysts is 18.5, meaning bulls need an upside of 96.27% from its current market value. According to analyst projections, NKTR’s forecast low is 6 with 24 as the target high. To hit the forecast high, the stock’s price needs a -3378.26% plunge from its current level, while the stock would need to soar -769.57% for it to hit the projected low.
Nektar Therapeutics (NKTR) estimates and forecasts
Year-over-year growth is forecast to reach -59.34% down from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of 9.74M. 8 analysts are of the opinion that Nektar Therapeutics’s revenue for the current quarter will be 9.84M. The company’s revenue for the corresponding quarters a year ago was 23.49M and 24.12M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -58.54%. The estimates for the next quarter sales put growth at -59.23%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 25.49%. The 2025 estimates are for Nektar Therapeutics earnings to decrease by -38.79%, but the outlook for the next 5-year period is at -16.46% per year.
NKTR Dividends
Nektar Therapeutics is expected to release its next quarterly earnings report in June.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.2575% or 15.16 million shares worth $18.79 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 6.65 shares estimated at $4.56 million under it, the former controlled 3.57% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 3.08% of the shares, roughly 5.72 shares worth around $3.92 million.
